SCHEMBL5724192

SCHEMBL5724192

CC(C)(C)C1CN(c2nc(CN3C(=O)c4ccccc4C3=O)cs2)C1O[SiH](c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
RECQL P46063 1/20 0.36
PKM P14618 2/20 0.35
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 4/20 0.34
POLB P06746 3/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
HPGD P15428 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ACHE P22303 2/20 0.32
RXFP1 Q9HBX9 1/20 0.31
KDM4E B2RXH2 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723661 0.80 NPC1 (0.33) LMNASMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL5723931 0.79 KDM4E (0.43) MAPTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL5724296 0.78 KDM4E (0.44) MAPTPKMLMNASMN1; SMN2ALDH1A1
SCHEMBL5724580 0.77 HTR2B (0.31) MAPTALDH1A1
SCHEMBL5724737 0.77 LDHA (0.41) ALDH1A1POLBL3MBTL1CYP1A2CYP2C9
SCHEMBL5723878 0.76 HSD17B10 (0.41) MAPTLMNASMN1; SMN2NPSR1ALDH1A1
SCHEMBL5724075 0.76 SCD (0.40) CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL5724331 0.75 USP30 (0.32)
SCHEMBL5723789 0.75 HPGD (0.52) MAPTLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL6839029 0.74 ACKR3 (0.35) SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD MAPT 2574/4885RECQL 4233/4885PKM 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.